TY  - JOUR
AU  - Goldschmidt, Hartmut
AU  - Baertsch, Marc-Andrea
AU  - Schlenzka, Jana
AU  - Becker, Natalia
AU  - Habermehl, Christina
AU  - Hielscher, Thomas
AU  - Raab, Marc-Steffen
AU  - Hillengass, Jens
AU  - Sauer, Sandra
AU  - Müller-Tidow, Carsten
AU  - Luntz, Steffen
AU  - Jauch, Anna
AU  - Hose, Dirk
AU  - Seckinger, Anja
AU  - Brossart, Peter
AU  - Goerner, Martin
AU  - Klein, Stefan
AU  - Schmidt-Hieber, Martin
AU  - Reimer, Peter
AU  - Graeven, Ullrich
AU  - Fenk, Roland
AU  - Haenel, Mathias
AU  - Martin, Hans
AU  - Lindemann, Hans W
AU  - Scheid, Christoph
AU  - Nogai, Axel
AU  - Salwender, Hans
AU  - Noppeney, Richard
AU  - Besemer, Britta
AU  - Weisel, Katja
TI  - Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE.
JO  - Leukemia
VL  - 35
IS  - 4
SN  - 1476-5551
CY  - London
PB  - Springer Nature
M1  - DKFZ-2020-01497
SP  - 1134-1144
PY  - 2021
N1  - 2021 Apr;35(4):1134-1144
AB  - The role of salvage high-dose chemotherapy and autologous stem cell transplantation (sHDCT/ASCT) for relapsed and/or refractory multiple myeloma (RRMM) in the era of continuous novel agent treatment has not been defined. This randomized, open-label, phase III, multicenter trial randomized patients with 1st-3rd relapse of multiple myeloma (MM) to a transplant arm (n = 139) consisting of 3 Rd (lenalidomide 25 mg, day 1-21; dexamethasone 40 mg, day 1, 8, 15, and 22; 4-week cycles) reinduction cycles, sHDCT (melphalan 200 mg/m2), ASCT, and lenalidomide maintenance (10 mg/day) or to a control arm (n = 138) of continuous Rd. Median PFS was 20.7 months in the transplant and 18.8 months in the control arm (HR 0.87; 95
LB  - PUB:(DE-HGF)16
C6  - pmid:32694619
DO  - DOI:10.1038/s41375-020-0948-0
UR  - https://inrepo02.dkfz.de/record/157227
ER  -